Main Library
Fortune 500 company DaVita is one of the largest kidney care companies in the United States. It has about $5 billion at risk in value-based contracts and is on a pathway to have about $10 billion at risk for patients with kidney disease. Jeff Giullian, M.D., chief medical officer at DaVita, recently spoke with Healthcare Innovation about some of the things alternative payment models are allowing the company to do to provide more holistic care to patients.